Skip to main content
. Author manuscript; available in PMC: 2024 Sep 3.
Published in final edited form as: Target Oncol. 2023 Jun 26;18(4):601–610. doi: 10.1007/s11523-023-00980-8

Table 5.

Univariable and multivariable conditional logistic regression analysis of irH risk factors

Model type OR (95% CI) p-Value
Unadjusted model
Liver metastasis at ICI initiation 2.14 (1.15 to 3.96) 0.015
History of cirrhosis 0.40 (0.14 to 1.11) 0.080
Adjusted model 1—adjusted for ECOG Performance Score, history of autoimmune disease, Hepatitis B and Hepatitis C
Liver metastasis at ICI initiation 2.46 (1.25 to 4.85) 0.009
History of cirrhosis 0.14 (0.02 to 0.74) 0.020
Adjusted model 2—adjusted for dual ICI, ECOG Performance Score, history of autoimmune disease, Hepatitis B and Hepatitis C
Liver metastasis at ICI initiation 2.79 (1.37 to 5.66) 0.005
History of cirrhosis 0.14 (0.02 to 0.75) 0.022

CI confidence interval, ECOG Eastern Cooperative Oncology Group, ICI immune checkpoint inhibitor, irH immune-related hepatitis, OR odds ratio